Comparison of the Efficacy of Single or Double Intravesical Epirubicin Instillation in the Early Postoperative Period to Prevent Recurrences in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Prospective, Randomized Multicenter Study

Basit Öğe Kaydı
dc.contributor.authorTurkeri, Levent
dc.contributor.authorTanidir, Yiloren
dc.contributor.authorCal, Cag
dc.contributor.authorOzen, Haluk
dc.contributor.authorSahin, Hayrettin
dc.date.accessioned2024-04-24T17:14:27Z
dc.date.available2024-04-24T17:14:27Z
dc.date.issued2010
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: To investigate the efficacy of single or double epirubicin instillation during the early postoperative period (EPP) in intermediate-risk non-muscle-invasive urothelial cancer. Methods: Patients with primary and solitary or multiple (3 or less) Ta (grade 2-3) or T1 (grade 1-2) tumors were enrolled. Patients were randomized to receive either a single dose of 100 mg epirubicin instillation within 6 h or a second 100 mg epirubicin instillation during the 12th-18th hours after a complete TUR-BT. At the end of the 60-month follow-up period, the available data were statistically analyzed. The end-points of the study were determined as disease-free survival, progression and recurrence rates, time to recurrence, and time to progression. Results: A total of 299 patients from 24 institutions were randomized between January 2002 and June 2004. There were 143 patients from 18 institutions who met the eligibility criteria. The follow-up and disease-free survival periods were 16.9 months and 16 months, respectively. There was no statistical difference in the demographic properties and the end-points between the groups. Conclusions: A single dose of intravesical 100 mg epirubicin chemotherapy during the early postoperative period for primary intermediate-risk non-muscle-invasive urothelial cancer achieved 16 months of mean disease-free survival. A second intravesical epirubicin instillation did not provide any significant benefit. Copyright (C) 2010 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000300571
dc.identifier.endpage265en_US
dc.identifier.issn0042-1138
dc.identifier.issn1423-0399
dc.identifier.issue3en_US
dc.identifier.pmid20332605
dc.identifier.scopus2-s2.0-78049483585
dc.identifier.scopusqualityQ2
dc.identifier.startpage261en_US
dc.identifier.urihttps://doi.org/10.1159/000300571
dc.identifier.urihttps://hdl.handle.net/11468/17959
dc.identifier.volume85en_US
dc.identifier.wosWOS:000283550200003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofUrologia Internationalis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBladder Cancer, Non-Muscle-Invasiveen_US
dc.subjectIntravesical Chemotherapyen_US
dc.subjectEpirubicinen_US
dc.subjectRecurrence-Free Survivalen_US
dc.titleComparison of the Efficacy of Single or Double Intravesical Epirubicin Instillation in the Early Postoperative Period to Prevent Recurrences in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Prospective, Randomized Multicenter Studyen_US
dc.titleComparison of the Efficacy of Single or Double Intravesical Epirubicin Instillation in the Early Postoperative Period to Prevent Recurrences in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Prospective, Randomized Multicenter Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu